Skip to main content
CRBP
NASDAQ Life Sciences

Corbus Pharmaceuticals Secures FDA Alignment for CRB-701 Registrational Path in HNSCC and Cervical Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$10.875
Mkt Cap
$179.848M
52W Low
$4.64
52W High
$20.56
52W Position info
134% above low
Off High info
47% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

CRBP has more than doubled off its 52-week low of $4.64.

Summary

Corbus Pharmaceuticals announced broad alignment with the FDA on the registration path for its lead oncology drug candidate, CRB-701, in two indications, enabling progression to registrational studies for potential accelerated approval. The company also announced the planned resignation of its Chief Medical Officer.


Key Events · Product Development and Regulatory · CRBP

  • FDA Alignment for CRB-701

    Corbus Pharmaceuticals announced broad alignment with the FDA on the registration path for CRB-701, its Nectin-4 targeting ADC, in second-line head and neck squamous cell carcinoma (HNSCC) and cervical cancer.

  • Registrational Study Design Agreed

    The company has agreed upon second-line registrational study designs for CRB-701, intended to support potential accelerated approval using objective response rate (ORR) as the primary endpoint, with potential full approval granted on overall survival (OS) benefit.

  • Upcoming Data Presentation

    Updated clinical data from the Phase 1/2 study of CRB-701 in both HNSCC and cervical cancer will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

  • Chief Medical Officer Resignation

    Dr. Dominic Smethurst, the company's Chief Medical Officer, will step down from his role effective June 30, 2026, as part of a strategic transition for late-stage development.


Analysis · CRBP · Life Sciences

This 8-K filing details a significant positive development for Corbus Pharmaceuticals, as it has achieved broad alignment with the FDA on the registration path for CRB-701 in second-line HNSCC and cervical cancer. This clarity on study design and endpoints for potential accelerated approval substantially de-risks the development of a key pipeline asset and provides a clear pathway to market. The company plans to initiate a registrational study in mid-2026 and will present updated clinical data at ASCO 2026. While the Chief Medical Officer's resignation is noted, the company frames it as part of a strategic transition to prepare for late-stage development, mitigating its negative impact. This regulatory clarity is a strong positive signal for the company's oncology pipeline.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBP was trading at $10.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $179.8M. The 52-week trading range was $4.64 to $20.56. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBP - Latest Insights

CRBP
Nov 16, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.45
Real-time Price: $3.18 info
Change: -$0.2675 (-8%) info
Market Cap: $66.354M info
CRBP
Nov 10, 2026, 8:08 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.52
Real-time Price: $3.18 info
Change: -$0.340 (-10%) info
Market Cap: $66.354M info
CRBP
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $7.08
Real-time Price: $3.18 info
Change: -$3.90 (-55%) info
Market Cap: $66.354M info
CRBP
Sep 14, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $9.26
Real-time Price: $3.18 info
Change: -$6.08 (-66%) info
Market Cap: $66.354M info
CRBP
Sep 14, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $8.91
Real-time Price: $3.18 info
Change: -$5.73 (-64%) info
Market Cap: $66.354M info